THPO抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using THPO mouse mAb (green) and negative control (red).    

  
  

Thrombopoietin (THPO) is a glycoprotein hormone primarily produced in the liver and kidneys, playing a critical role in regulating platelet production by binding to the c-MPL receptor on megakaryocytes, promoting their proliferation and differentiation. THPO antibodies, which target this hormone or its receptor, have garnered attention in both research and clinical contexts. In diagnostic settings, anti-THPO antibodies are used to measure THPO levels in conditions like thrombocytopenia or myeloproliferative disorders, where dysregulated THPO signaling may contribute to abnormal platelet counts.

Autoantibodies against THPO or c-MPL are implicated in certain autoimmune disorders, such as immune thrombocytopenia (ITP), where they disrupt normal thrombopoiesis. Additionally, therapeutic anti-THPO receptor agonists (e.g., romiplostim, eltrombopag) mimic THPO activity to stimulate platelet production, offering treatment for chronic ITP or chemotherapy-induced thrombocytopenia. Conversely, neutralizing antibodies against THPO or its receptor are explored in conditions with pathological platelet overproduction, such as essential thrombocythemia. Research on THPO antibodies continues to unravel their pathophysiological roles and therapeutic potential, bridging hematopoiesis regulation with clinical applications in hematologic diseases.